Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Buonomo Antonio Riccardo, Viceconte Giulio, Calabrese Massimiliano, De Luca Giovanna, Tomassini Valentina, Cavalla Paola, Maniscalco Giorgia Teresa, Ferraro Diana, Nociti Viviana, Radaelli Marta, Buscarinu Maria Chiara, Paolicelli Damiano, Gajofatto Alberto, Annovazzi Pietro, Pinardi Federica, Di Filippo Massimiliano, Cordioli Cinzia, Zappulo Emanuela, Scotto Riccardo, Gentile Ivan, Spiezia Antonio Luca, Petruzzo Martina, De Angelis Marcello, Brescia Morra Vincenzo, Solaro Claudio, Gasperini Claudio, Cocco Eleonora, Moccia Marcello, Lanzillo Roberta, Raising Italian Researchers in Multiple Sclerosis (RIREMS) study group
Аннотация
METHODS: Retrospective, multicentric study recruiting Italian MS patients treated with rituximab, ocrelizumab and cladribine.
RESULTS: We included 931 MS patients from 15 centers. All but 38 patients performed a complete HBV screening. Patients' age > 50 years was significantly associated with no history of vaccination and HBsAb titres < 100 mIU at baseline (p < 0.001). No significant correlation was found between post-vaccination HBsAb titres and type of treatment (p = 0.5), pre-or post-therapy vaccination (p = 0.2) and number of previous DMTs (p = 0.2). Among pOBI patients (n = 53), 21 received antiviral prophylaxis, while only 13 had HBV DNA monitoring and 19 patients neither monitored HBV DNA nor received prophylaxis.
CONCLUSIONS: Baseline HBV screening in patients receiving anti-CD20 and cladribine is a consolidated practice. Nonetheless, HBV vaccination coverage is still lacking in such population and age is a significant factor associated with low HBV protection. Rituximab, ocrelizumab and cladribine did not impair HBV vaccine response. Almost 35% of pOBI patients fail to receive HBVr prevention. Management of HBV prophylaxis could be improved in MS patients and further prospective studies are needed to assess the effectiveness of prophylactic strategies in such patients.